Wang Y.Johnston S.C.Bath P.M.Grotta J.C.Pan Y.Amarenco P.Wang Y.Simon T.Kim J.S.JIANN-SHING JENGLiu L.Lin Y.Wong K.S.L.Wang D.Li H.2021-12-222021-12-2220199598146https://www.scopus.com/inward/record.uri?eid=2-s2.0-85062322312&doi=10.1136%2fbmj.l895&partnerID=40&md5=9075052ad14e4bbdff4fa75cf23cb121https://scholars.lib.ntu.edu.tw/handle/123456789/590425[SDGs]SDG3acetylsalicylic acid; clopidogrel; cytochrome P450 2C19; antithrombocytic agent; ABCD2 score; Article; atherosclerosis; bleeding; brain ischemia; cost effectiveness analysis; CYP2C19 gene; dual antiplatelet therapy; feasibility study; gene frequency; genetic polymorphism; human; loss of function mutation; minor ischemic stroke; National Institutes of Health Stroke Scale; pharmacogenetics; population research; practice guideline; priority journal; recurrent disease; risk factor; scoring system; secondary prevention; transient ischemic attack; treatment duration; cerebrovascular accident; combination drug therapy; drug administration; time factor; transient ischemic attack; Drug Administration Schedule; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Time Factorsjournal article10.1136/bmj.l895308196872-s2.0-85062322312